IL-1β (and not TNFα or IFNy) best reflects granuloma response in this in vitro model and, therefore, may be a useful biomarker for future clinical studies in sarcoidosis (Prior et al., 1996; Mikuniya et al., 2000). Here, IL1B is linked to sarcoidosis.